Recent Updates
Recently added Catalysts

monoflurophosphate

Phase 2

Caries | Small molecule | Other |GSK plc|Last Updated: Oct 1, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment100
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01657877Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate DentifricePHASE2 COMPLETED 100May 1, 2012Jun 1, 2013Oct 1, 20141 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage (%) Change in Surface Microhardness (SMH) Following 21 Days of Twice Daily Treatment With the 1500 Ppm Fluoride + 5% CSP Dentifrice and With the 1500 Ppm Fluoride Dentifrice.
Baseline to 21 days

Percent SMH recovery (SMHR) was calculated from hardness values of enamel specimens at baseline (B), after in-situ hardening (R) and after first demineralization challenge (D1) using formula: \[(D1-R)/ (D1-B)\]\*100. A greater percentage change in SMHR represents a better remineralisation and hence a better outcome.

Secondary Endpoints
Percentage (%) Change in SMH Following 21 Days of Twice Daily Treatment With 500 Ppm Fluoride as SMFP and 0 % CSP Dentifrice, 0 Ppm Fluoride and 0% CSP, and 0 Ppm Fluoride and 5 % CSP.
Baseline to 21 days
Enamel Fluoride Uptake (EFU)
Baseline to 21 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
CSP/SMFP DentifriceEXPERIMENTALDentifrice containing high fluoride content as SMFP and CSP
SMFP Dentifrice Prototype 1ACTIVE_COMPARATORDentifrice containing high fluoride content as SMFP and no CSP
SMFP Dentifrice Prototype 2ACTIVE_COMPARATORDentifrice containing low fluoride content as SMFP and no CSP
CSP DentifriceACTIVE_COMPARATORDentifrice containing CSP but no fluoride
Placebo DentifricePLACEBO_COMPARATORDentifrice containing no CSP and no fluoride
Interventions
NameTypeDescription
Calcium sodium phosphosilicateDRUGCSP high percentage weight by weight
Sodium monoflurophosphateDRUG500 to 1500 parts per million (ppm) of fluoride
PlaceboDRUGNo CSP and no fluoride
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Wears a removable bilateral mandibular partial denture that has good stability and support, with sufficient room on each side in the posterior buccal flange area to accommodate two enamel specimens \[required dimensions 12 x 7 millimeters (mm)\].

Countries:United States
Unlock Eligibility Criteria